-
From Surface Tags to Synaptic Mechanism
2026-08-11
A translational framework for using Sulfo-NHS-SS-Biotin to connect neuronal receptor surface expression with calcium signaling, affinity workflows, and mechanistic decision-making.
-
ROS-Degradable LNPs for Tumor-Selective mRNA
2026-08-10
The reference study developed a combinatorial library of thioketal-containing, ROS-degradable lipids and identified BAmP-TK-12 as a preferential mRNA carrier for tumor cells. Delivery of DUF5 mRNA enabled mutant RAS depletion and produced stronger antitumor effects than a small-molecule RAS inhibitor in the reported models, while also highlighting important limits in selectivity, biodistribution, and translational validation.
-
AG-490 Workflow for JAK2/STAT6 Signaling Studies
2026-08-09
AG-490 (Tyrphostin B42) provides a reversible pharmacological approach for testing how exosomal SNORD52 influences JAK2/STAT6 activity and macrophage polarization. This workflow combines pathway-resolved phosphoprotein analysis with exosome and viability controls, helping distinguish on-target signaling effects from multi-kinase or cytotoxic artifacts.
-
ClpP Activation and Cell-Cycle Arrest in Lung Cancer
2026-08-08
The reference study identifies ZK53 as a selective activator of human mitochondrial ClpP and shows that mitochondrial proteostasis disruption can suppress lung squamous cell carcinoma. Its integrated structural, cellular, and in vivo evidence connects ClpP hyperactivation with impaired oxidative phosphorylation, ATM-mediated DNA damage response signaling, and cell-cycle arrest.
-
E-64: From Cathepsin Inhibition to Assay Insight
2026-08-07
E-64 is an irreversible L-trans-epoxysuccinyl peptide for cysteine protease inhibition. This article explains how a phenotype-negative renal study improves experimental design, target-engagement analysis, and interpretation of cathepsin assays.
-
HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit: Evidence &
2026-08-07
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit enables efficient, customizable fluorescent RNA probe synthesis for in situ hybridization and Northern blotting. This Cy3 RNA labeling kit balances high transcription yields with controlled Cy3-UTP incorporation, supporting reproducible detection of RNA targets in research applications. Rigorous evidence and workflow parameters are provided for optimal experimental performance.
-
SM-102: High-Purity Lipid for mRNA Delivery and Vaccine Syst
2026-08-06
SM-102, a synthetic lipid (heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate), enables efficient mRNA vaccine delivery as a critical lipid nanoparticle component. Its high purity and evidence-backed role in endosomal escape underpin its growing application in mRNA-based therapies.
-
SW033291: Unlocking 15-PGDH Inhibition for Regenerative Medi
2026-08-06
SW033291, a best-in-class 15-PGDH inhibitor, is transforming tissue regeneration and muscle repair research, especially in the context of GLP-1 receptor agonist–induced weight loss. This thought-leadership article provides mechanistic insight, translational guidance, and protocol recommendations for leveraging SW033291 in advanced regenerative workflows. Integrating recent breakthroughs, strategic analysis, and APExBIO’s product intelligence, it equips researchers to drive the next wave of muscle and hematopoietic stem cell innovation.
-
Dorsomorphin 2HCl: AMPK Inhibitor Applications & Protocol Ma
2026-08-05
Dorsomorphin 2HCl stands out as a robust AMPK inhibitor, empowering researchers to dissect metabolic and BMP signaling pathways with precision. This guide translates recent breakthroughs—especially in hepatic lipid research—into actionable workflows and troubleshooting strategies.
-
Mitochondrial Calcium Signaling Suppresses Ferroptosis in Ca
2026-08-05
This study reveals that mitochondrial calcium uptake, mediated by the MCU channel, preserves GPX4 activity via acetylation and thereby represses ferroptotic cell death in cancer models. The findings establish a mechanistic link between mitochondrial metabolism, protein acetylation, and tumor cell survival, with important implications for epigenetic and cancer research.
-
Hydrogen Gas Suppresses Cervical Cancer via HIF-1α and NF-κB
2026-08-04
This study elucidates how hydrogen gas inhalation exerts antitumor effects in cervical cancer models, specifically by reducing HIF-1α and NF-κB p65 expression and oxidative stress. High-throughput RNA sequencing provides mechanistic insight, suggesting new directions for therapeutic intervention and experimental design in cancer research.
-
Ibotenic Acid: NMDA Receptor Agonist for Neurodegenerative M
2026-08-04
Ibotenic acid is a gold-standard NMDA receptor agonist for creating robust animal models of neurodegenerative disorders. This guide translates new dose-response insights, workflow refinements, and troubleshooting methods into actionable protocols that empower neuroscience research with APExBIO’s high-purity compound.
-
ISRIB (trans-isomer): Unveiling Cognitive Rescue via ISR Inh
2026-08-03
Explore how ISRIB (trans-isomer), a potent PERK inhibitor, uniquely enables cognitive memory enhancement and mechanistic insights into inflammation-induced forgetting. Discover advanced protocols, scientific breakthroughs, and practical guidance for ER stress research.
-
Gepotidacin Versus Nitrofurantoin in UTI: Rigorous Phase 3 E
2026-08-03
The EAGLE-2 and EAGLE-3 phase 3 trials rigorously compared oral gepotidacin, a new triazaacenaphthylene antibiotic, to nitrofurantoin for uncomplicated urinary tract infection treatment. Gepotidacin demonstrated non-inferiority and, in one trial, superiority, offering a promising oral option against common and resistant uropathogens with an acceptable safety profile.
-
ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR
2026-08-02
The referenced study introduces a combinatorial library of reactive oxygen species (ROS)-degradable lipid nanoparticles that preferentially deliver mRNA into tumor cells, exploiting elevated ROS for targeted release. This strategy enhances the efficacy and selectivity of mRNA-based therapies, providing a robust platform for precision cancer treatment and advanced functional genomics.